Markets

Stock Alert: Verona Pharma Loses 14%

(RTTNews) - Shares of UK-based clinical-stage biopharmaceutical company Verona Pharma plc (VRNA) are falling more than 14 percent or $1.47 in Monday's morning trade at $8.73, after recording strong gains in the previous trading session on Friday.

Verona Pharma's stock had surged on Friday following news that it raised about $200 million in an oversubscribed private placement and subscription with new as well as existing institutional and accredited investors. The company plans to initiate a phase III program of Ensifentrine in chronic obstructive pulmonary disease, dubbed ENHANCE, later this year.

Verona Pharma has traded in a range of $2.01 to $15.71 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VRNA

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More